OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. Several other brokerages have also recently weighed in on OCX. Needham & Company LLC reiterated a buy rating and issued a $4.25 price objective on shares of OncoCyte […]

Related Keywords

United States , Andrew Arno , Oncocyte Corporation , Needham Company , Securities Exchange Commission , Oncocyte Company Profile , Free Report , Director Andrew Arno , Exchange Commission , Broadwood Partners , Get Free Report , Cyte Corporation , Oncocyte Daily ,